IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide.
Dubbink HJ, Taal W, van Marion R, Kros JM, van Heuvel I, Bromberg JE, Zonnenberg BA, Zonnenberg CB, Postma TJ, Gijtenbeek JM, Boogerd W, Groenendijk FH, Smitt PA, Dinjens WN, van den Bent MJ.
Dubbink HJ, et al. Among authors: van heuvel i, van marion r, van den bent mj.
Neurology. 2009 Nov 24;73(21):1792-5. doi: 10.1212/WNL.0b013e3181c34ace.
Neurology. 2009.
PMID: 19933982
Clinical Trial.